Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UCB Buoyed By Strong First-Half, Lupus Ambitions Undented

This article was originally published in The Pink Sheet Daily

Executive Summary

The Belgian-headquartered company has advanced a second potential lupus drug into clinical trials after disappointing Phase III results with its first, and is monitoring closely the effects of biosimilars in Europe on its marketed TNF-inhibitor Cimzia.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register